๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT07382375Aortic Aneurysm and Dissection
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
NCT07470840Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2
27
Fuzhou
2027-02-01
Not yet open
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT07314203Gastric Cancer, Surgery
Fujian Medical University
Phase 3
118
Fuzhou
2026-12-25
Not yet open
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484Heart Failure Due to Coronary Artery Disease
Shanghai Zhongshan Hospital
Phase 3
1,526
Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an
2026-11-01
Not yet open
Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection
NCT07672496Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response, Sepsis, Immune Dysfunction
Fujian Medical University Union Hospital
Not applicable
165
Fuzhou
2026-10-30
Not yet open
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
NCT07788001Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG)
Fujian Medical University Union Hospital
Phase 3
200
Fuzhou
2026-10-01
Not yet open
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Not yet open
Early Lumbar Drainage for Intraventricular Hemorrhage
NCT07625449Intraventricular Hemorrhage, Cerebral Hemorrhage
Second Affiliated Hospital of Nanchang University
Not applicable
392
Fuzhou, Jinan, Taizhou, Changde, Dezhou, Ganzhou, Guiyang, Hangzhou
2026-10
Not yet open
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
NCT07766772HER2 + Breast Cancer, Advanced Breast Cancer
Fujian Cancer Hospital
Phase 2
50
Fuzhou
2026-09-30
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-30
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
Vividion Therapeutics, Inc.
Phase 2
140
Bengbu, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Jinan, Shanghai
2026-09-11
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459Idiopathic Pulmonary Fibrosis
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
Circadian-Synchronized Breast Milk Feeding and Sleep in Preterm Infants: A Multicenter Randomized Controlled Trial
NCT07645677Preterm Infant, Sleep
Shanghai Jiao Tong University School of Medicine
Not applicable
120
Fuzhou, Nantong, Shanghai, Zhangjiagang
2026-09-01
Not yet open
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 3
380
Bengbu, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei, Guangzhou
2026-09-01
Not yet open
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
NCT07613567Locally Advanced Cervical Carcinoma
Fujian Cancer Hospital
Phase 3
486
Fuzhou
2026-09-01
Not yet open
A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers
NCT07613905Hypersensitivity Reaction
Fujian Cancer Hospital
Not applicable
380
Fuzhou
2026-09-01
Not yet open
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
930
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-09
Not yet open
AI-Assisted Patient Support in mHSPC
NCT07804030Metastatic Prostate Cancer
Fudan University
Not applicable
160
Fuzhou, Shanghai, Kunming, Wenzhou
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2
160
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Chengdu, Hangzhou
2026-08-31
Recruiting
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
NCT07796789Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-08-30
Recruiting
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
NCT07730190Advanced Malignancies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Not yet open
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
NCT07683806Seborrheic Dermatitis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Not yet open
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2026-08-22
Not yet open
QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study
NCT07649473Colon Cancer, Synchronous Liver Metastases
Fujian Medical University
Phase 2
30
Fuzhou
2026-08-15
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667Esophageal Squamous Cell Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Haโ€™erbin, Jinan, Kunming, Luoyang
2026-08-13
Not yet open
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
NCT07469306Locally Advanced Rectal Cancer
Fujian Cancer Hospital
Phase 2
130
Fuzhou, Longyan, Quanzhou
2026-08-10
Not yet open
Optimizing Parameters of Transcranial Temporal Interference Stimulation for Spinocerebellar Ataxia Type 3
NCT07743866Spinocerebellar Ataxia Type 3
First Affiliated Hospital of Fujian Medical University
Not applicable
24
Fuzhou
2026-08-07
Not yet open
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
NCT07771764ALK-positive Non Small Cell Lung Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors
NCT07769229Gynecological Malignancies, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
126
Fuzhou
2026-08
Not yet open
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
NCT07740564Dry Eye
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08
Not yet open
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861Cirrhosis With Spontaneous Bacterial Peritonitis
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan, Changsha
2026-07-31
Recruiting
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
NCT07528183Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
62
Fuzhou, Guangzhou, Nanning, Wuhan
2026-07-22
Recruiting
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT07596784Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-20
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Not yet open
Development and Validation of a Colorectal Cancer Diagnostic Model
NCT07692555Colorectal Cancer, Advanced Neoplasia, Prediction Models, Risk Stratification
Peking University Cancer Hospital & Institute
Observational
20,000
Beijing, Fuzhou, Xiamen, Yinchuan
2026-07-15
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Recruiting
A Study of HLX18 vs. OPDIVOยฎ in Multiple Resected Solid Tumors
NCT07518043Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
Shanghai Henlius Biotech
Phase 1
174
Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
2026-07-15
Recruiting
Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock
NCT07560085Cardiogenic Shock
ForQaly Medical (Shanghai) Co., Ltd
Not applicable
60
Fuzhou, Wuhan
2026-07-14
Recruiting
DAREONยฎ-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124Head and Neck Squamous Cell Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07660432Neoplasms, Malignant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
472
Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou
2026-07-03
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai
2026-07-02
Not yet open
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,832
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zhengzhou
2026-07-01
Recruiting
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
NCT07693959MIBC
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Not yet open
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
NCT07667517Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
First Affiliated Hospital of Zhejiang University
Phase 4
148
Chongqing, Fuzhou, Foshan, Guangzhou, Nantong, Suqian, Suzhou, Xi'an
2026-07-01
Not yet open
Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome
NCT07658469Cognition Disorders, Aged
Fujian Provincial Hospital
Not applicable
106
Fuzhou
2026-07-01
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Not yet open
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
NCT07691333HR+/HER2- Breast Cancer, Breast Neoplasms
Fujian Cancer Hospital
Phase 2
35
Fuzhou, Quanzhou
2026-06-30
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186Heart Failure
Tasly Pharmaceutical Group Co., Ltd
Phase 3
636
Bozhou, Hefei, Suzhou, Beijing, Fuzhou, Lanzhou, Qingyang, Dongguan
2026-06-22
Not yet open
Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation
NCT07597564General Anesthesia; Tracheal Intubation
Fujian Provincial Hospital
Phase 4
900
Fuzhou
2026-06-22
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Recruiting
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
NCT07726953Acute Respiratory Distress Syndrome
Southeast University, China
Not applicable
500
Beijing, Changchun, Chengdu, Chenzhou, Dalian, Fuzhou, Guangzhou, Hangzhou
2026-06-16
Recruiting
Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS
NCT07726940Acute Respiratory Distress Syndrome (ARDS)
Southeast University, China
Observational
1,776
Beijing, Fuzhou, Nanjing, Jinan, Chengdu, Hangzhou, Changchun, Chenzhou
2026-06-16
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248Primary Immune Thrombocytopenia
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042Obesity, Weight Control
Shanghai Zhongshan Hospital
Not applicable
420
Chongqing, Fuzhou, Xiamen, Wuhan, Nanjing, Suzhou, Shanghai, Luzhou
2026-06-10
Active, closed
A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants
NCT07610148Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
21
Fuzhou
2026-06-08
Recruiting
A Phase I Study of JSKN021 in Advanced Solid Tumors
NCT07617727Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
199
Fuzhou, Nanning, Harbin, Wuhan, Nanjing, Xuzhou, Jining, Shanghai
2026-06-02
Recruiting
Preventive Narrative Exposure Intervention for PTSD in ICU Patients After Cardiopulmonary Bypass Cardiac Surgery
NCT07632131Cardiopulmonary Bypass, Intensive Care Units, Stress Disorders, Post-Traumatic
First Affiliated Hospital of Fujian Medical University
Not applicable
100
Fuzhou
2026-06-02
Not yet open
Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery
NCT07628543Thyroid Diseases, Thyroid Neoplasms
Fujian Medical University
Observational
100
Fuzhou
2026-06-01
Not yet open
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
NCT07406815Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green), Lymph Node Dissection
Fujian Medical University Union Hospital
Phase 3
144
Fuzhou
2026-06-01
Recruiting
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
NCT07702708HR+/HER2- Breast Cancer, Breast Neoplasms
Fujian Cancer Hospital
Observational
100
Fuzhou, Quanzhou, Ningde, Sanming
2026-06-01
Not yet open
Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery
NCT07576517Older Patients, Surgery, Dexmedetomidine, Esketamine
Peking University First Hospital
Phase 4
1,160
Beijing, Fuzhou, Shenzhen, Xi'an, Hangzhou
2026-06
Not yet open
Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery
NCT07576543Older Patients, Surgery, Dexmedetomidine, Esketamine
Peking University First Hospital
Phase 4
1,160
Beijing, Fuzhou, Shenzhen, Xi'an, Hangzhou
2026-06
Recruiting
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT06993506HER2-negative Breast Cancer, Recurrence, Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPROยฎ in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587Multiple Myeloma (MM)
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-27
Recruiting
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
NCT07279935Non-small Cell Lung Cancer
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
BeOne Medicines
Phase 3
1,056
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Haikou
2026-05-22
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, HangzhouZhejiang
2026-05-21
Recruiting
A Study of SKB571 in Participants With Gastrointestinal Tumors
NCT07564466Gastrointestinal Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
A Phase โ…ก/โ…ข Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143Colorectal (Colon or Rectal) Cancer
RemeGen Co., Ltd.
Phase 2/3
80
Beijing, Chongqing, Fuzhou, Meizhou, Nanjing, Shijiazhuang, Zhengzhou, Wuhan
2026-05-12
Recruiting
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT07379047GIST - Gastrointestinal Stromal Tumor, Advanced
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3
255
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Shijiazhuang
2026-05-11
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Not yet open
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07625514Gout Flare
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
264
Fuzhou, Hangzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-07
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
670
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanjing
2026-05-04
Not yet open
Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial
NCT07616531Gout Flares
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
118
Hangzhou, Fuzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-01
Not yet open
Clinical Study of Universal CD19 CAR-ฮณฮด T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
NCT07491263Relapsed/Refractory CD19-positive B-ALL
Fujian Medical University
Phase 1
6
Fuzhou
2026-05-01
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161Alzheimer Disease
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
A Phase โ… b/โ…กa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
NCT07593027Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Not yet open
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
NCT07566247Advanced Malignant Solid Tumors
Akeso
Phase 1
96
Fuzhou, Dongguan, Wuhan
2026-04-30
Recruiting
Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07562438Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
20
Fuzhou
2026-04-29
Recruiting
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
NCT07474727Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599High-risk Localized Prostate Cancer
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
Recruiting
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Active, closed
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
NCT07338942ATTR-CM
AstraZeneca
Not applicable
4,000
Beijing, Changlexi, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangdong Province
2026-04-21
Recruiting
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
NCT07513844Huntington Disease
First Affiliated Hospital of Fujian Medical University
Not applicable
24
Fuzhou
2026-04-20
Recruiting
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
NCT07235319Nasopharangeal Cancer, Distant Metastasis
Sun Yat-sen University
Phase 3
260
Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning
2026-04-16
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Recruiting
Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis
NCT07542938Symptomatic Intracranial Atherosclerotic Stenosis
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Recruiting
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
NCT07496229T-cell Lymphomas
Dizal Pharmaceuticals
Phase 1/2
165
Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou
2026-04-15
Recruiting
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
NCT07478302Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
36
Fuzhou, Nanning
2026-04-14
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Rows per page Showing 1–100 of 1018
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuzhou), 1,018 studies
PhaseStudiesRecruitingShare
Phase 337617036.9%
Phase 21539215%
Observational1318712.9%
Not applicable1066210.4%
Phase 1/299759.7%
Phase 171537%
Phase 2/338313.7%
Phase 429112.8%
Phase EARLY_PHASE115131.5%

Most active sponsors

Lead sponsors with the most studies (Fuzhou)
Lead sponsorStudiesRecruiting
AstraZeneca6233
First Affiliated Hospital of Fujian Medical University4535
Fujian Medical University Union Hospital3925
Merck Sharp & Dohme LLC3922
Fujian Cancer Hospital3516
Fujian Medical University3412
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2312
BeOne Medicines2215
Fujian Provincial Hospital2014
Bristol-Myers Squibb1814
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.